Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 19:14:1393278.
doi: 10.3389/fonc.2024.1393278. eCollection 2024.

Editorial: Updates on combination therapy for lung cancer volume II

Alberto Pavan  1 , Liyun Shi  2 , Muhammad Abbas  3
Affiliations
Editorial

Editorial: Updates on combination therapy for lung cancer volume II

Alberto Pavan et al. Front Oncol. .
No abstract available

Keywords: NSCLC; SCLC; anti-angiogeneic therapy; computational biology; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Updates on combination therapy for lung cancer volume II

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Med (Baltimore). (2023) 102:e32899. doi: 10.1097/MD.0000000000032899 - DOI - PMC - PubMed
    1. Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol. (2022) 12:877594. doi: 10.3389/fonc.2022.877594 - DOI - PMC - PubMed
    1. Garon EB, Visseren-Grul C, Rizzo MT, Puri T, Chenji S, Reck M. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review. Front Oncol. (2023) 13:1247879. doi: 10.3389/fonc.2023.1247879 - DOI - PMC - PubMed
    1. Yang B, Li Y, Deng J, Yang H, Sun X. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study. Front Oncol. (2023) 13:1210267. doi: 10.3389/fonc.2023.1210267 - DOI - PMC - PubMed

Publication types

LinkOut - more resources